Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel.

ABSTRACT:

Introduction

Drug prior authorization (PA) imposes a bureaucratic and economic burden on healthcare service providers and payers. A novel automated PA system may improve these drawbacks.

Methods

An historical cohort study from a large health maintenance organization in Israel, comparing manual versus automated PA mechanisms for diabetes mellitus (DM) drugs: sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogs (GLP1-A). We compared patients with DM, whose first drug applications were approved using the automated system, with similar patients whose first drug applications were approved by manual PA. The primary endpoint was the time elapsed from application approval to prescription filling (accessibility time). Secondary endpoints included th

SUBMITTER: Moshel S 

PROVIDER: S-EPMC10540583 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature